Recombinant human erythroid potentiating activity enhances the effect of erythropoietin in mice.
Endotoxin-free purified recombinant human erythroid potentiating activity (EPA) was administered to mice either alone or concomitantly with recombinant human erythropoietin (Epo). Epo treatment alone caused an increased hematocrit and reticulocyte count in the peripheral blood. In the spleen, the number of morphologically recognizable erythroid cells, CFU-E and BFU-E was also increased. Concomitant administration of EPA with Epo further enhanced erythropoiesis as judged by the same parameters. No significant effect on granulopoiesis was observed in association with Epo or combined Epo and EPA treatment. Our data indicates that EPA is active in vivo in augmenting the erythropoietic response to Epo.
Niskanen
E
E
Division of Hematology/Oncology, University of Virginia, Charlottesville.
Gasson
J C
JC
Egrie
J
J
Wipf
K
K
Golde
D W
DW
D000818:Animals; D001854:Bone Marrow Cells; D003114:Colony-Forming Units Assay; D004347:Drug Interactions; D004906:Erythrocyte Count; D015672:Erythroid Precursor Cells / Q000166:cytology; D004920:Erythropoiesis; D005260:Female; D006400:Hematocrit; D006801:Humans; D008222:Lymphokines / Q000494:pharmacology*; D051379:Mice; D008813:Mice, Inbred ICR; D011994:Recombinant Proteins / Q000494:pharmacology; D012156:Reticulocytes / Q000166:cytology; D013154:Spleen / Q000166:cytology; D019714:Tissue Inhibitor of Metalloproteinases
D008222:Lymphokines; D011994:Recombinant Proteins; D019714:Tissue Inhibitor of Metalloproteinases